PRIM-DJ2727 ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2
97	Ulcerative colitis	1

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03671785 (ClinicalTrials.gov)	May 15, 2019	12/9/2018	Study of the Fecal Microbiome in Patients With Parkinson's Disease	A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Parkinson's Disease	Parkinson Disease	Drug: PRIM-DJ2727;Drug: Placebo oral capsule	The University of Texas Health Science Center, Houston	Kelsey Research Foundation	Active, not recruiting	55 Years	75 Years	All	12	Phase 1	United States
2	NCT03026231 (ClinicalTrials.gov)	July 15, 2017	11/1/2017	Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients	A Prospective, Randomized Placebo Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Weekly Administration of Lyophilized PRIM-DJ2727 Given Orally in Subjects With Parkinson's Disease	Parkinson's Disease	Biological: PRIM-DJ2727;Drug: Placebo (for PRIM-DJ2727)	The University of Texas Health Science Center, Houston	Kelsey Research Foundation	Withdrawn	45 Years	70 Years	All	0	Phase 1/Phase 2	United States

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04373473 (ClinicalTrials.gov)	September 14, 2020	28/4/2020	Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis	A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation (PRIM-DJ2727) Administered Orally in Combination With Standard of Care Therapy for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis	Adults With Ulcerative Colitis	Drug: PRIM-DJ2727;Drug: Placebos	The University of Texas Health Science Center, Houston	NULL	Recruiting	18 Years	N/A	All	58	Phase 2	United States